Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) PT at $92.60

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received an average rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $92.60.

PBH has been the subject of a number of research analyst reports. Canaccord Genuity Group raised their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th. DA Davidson raised their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Finally, Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research report on Monday, December 9th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kestra Investment Management LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter worth about $27,000. CIBC Private Wealth Group LLC boosted its position in shares of Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. Huntington National Bank boosted its position in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after buying an additional 181 shares during the period. Finally, McIlrath & Eck LLC boosted its position in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after buying an additional 154 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $84.61 on Friday. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The business’s 50-day simple moving average is $80.04 and its two-hundred day simple moving average is $77.14. The stock has a market cap of $4.19 billion, a PE ratio of 19.81, a P/E/G ratio of 2.69 and a beta of 0.50. Prestige Consumer Healthcare has a 52 week low of $62.35 and a 52 week high of $88.36.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.